Research programme: Cyclin E1-directed degraders - Monte Rosa Therapeutics
Latest Information Update: 24 May 2024
At a glance
- Originator Monte Rosa Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action CCNE1 protein degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer